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Abstract
Background: Triggering receptor expressed on myeloid cells-2 (TREM2) exerts important functions in the regulation
of monocytes, like dendritic cells, osteoclasts, tissue macrophages, and microglia. Mutations in TREM2 are associated
with several diseases, including Nasu-Hakola disease, frontotemporal dementia, and Alzheimer’s disease (AD). TREM2
undergoes sequential proteolytic processing by ectodomain shedding and intramembrane proteolysis.
Findings: We show that inhibition of γ-secretase-dependent cleavage of the TREM2 C-terminal fragment in cellular
membranes interferes with TREM2-dependent signaling and cellular function. Inhibition of γ-secretase decreases
membrane-proximal signaling and intracellular Ca2+ response. Decreased signaling alters morphological changes
and phagocytic activity of cells upon selective stimulation of TREM2.
Conclusions: The data demonstrate the importance of γ-secretase-dependent intramembrane processing in TREM2-
mediated signaling and, thus, a functional relation of two AD-associated proteins.
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Findings
The triggering receptor expressed on myeloid cells-2
(TREM2) belongs to the immunoglobulin superfamily of
cell surface receptors and is expressed on monocyte-
derived cell types, including dendritic cells [1], osteo-
clasts, tissue macrophages, and microglia [2]. TREM2
associates with its co-receptor TYROBP/DNAX-activat-
ing protein of 12 kDa (DAP12). Upon activation of
TREM2, DAP12 undergoes phosphorylation at two tyro-
sine residues within its immunoreceptor tyrosine activa-
tion motif (ITAM). Phosphorylated DAP12 recruits and
activates the Syk protein kinase which mediates
mitogen-activated protein kinase (MAPK) and phospho-
lipase Cγ (PLCγ)-dependent signaling pathways [3].
TREM2 has been involved in the regulation of phagocyt-
osis and cytokine secretion, suggesting a role of TREM2
in clearance of neuronal debris and neuroinflammation
[4–6].
Mutations in either TREM2 or DAP12 can cause poly-
cystic lipomembranous osteodysplasia with sclerosing
leukoencephalopathy (PLOSL or Nasu-Hakola disease),
which is also characterized by presenile dementia in
homozygous carriers [7, 8]. Interestingly, TREM2 vari-
ants have recently been associated with late-onset Alz-
heimer’s disease (AD) and frontotemporal lobe dementia
(FTD) [8–10]. Notably, TREM2 was found to be upregu-
lated in microglia or myeloid cells surrounding char-
acteristic amyloid plaques in mouse models of AD
[11–13]. The role of TREM2 in the pathogenesis of
AD remains to be determined, and studies with trans-
genic mouse models showed controversial effects.
While deletion of TREM2 increases Aβ plaque load in
one transgenic mouse model of AD [14], another study ra-
ther revealed decreased Aβ plaques in the hippocampus
upon deletion of TREM2 [15]. TREM2 undergoes sequen-
tial proteolytic processing by ectodomain shedding and
intramembranous cleavage by γ-secretase [16–18]. Here,
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we assessed the functional relevance of γ-secretase in
membrane-proximal signaling of TREM2.
Inhibition of γ-secretase impairs TREM2-dependent Ca2+
signaling
TREM2 signaling involves the activation of PLCγ and
elevation of the cytosolic Ca2+ concentration [14, 18].
To investigate the role of γ-secretase in TREM2-
dependent signaling, we expressed a TREM2 variant
with an N-terminal myc tag and a C-terminal green
fluorescent protein (GFP) tag together with its co-
receptor DAP12. We previously showed that myc-tagged
TREM2 could be specifically activated by binding of
anti-myc antibodies leading to phosphorylation of its co-
receptor DAP12. The C-terminal GFP tag allowed the
identification of transfected cells but did not interfere
with the constitutive proteolytic processing of TREM2
[18]. Western immunoblotting with anti-myc and anti-
GFP antibodies revealed expression of full-length
TREM2 with the N- and C-terminal tags at ~60 kDa
(Fig. 1a). In addition, a ~38 kDa band was selectively de-
tected with the anti-GFP antibody representing a C-
terminal fragment (CTF) of TREM2 after ectodomain
shedding (Fig. 1a). Pharmacological inhibition of γ-
secretase with DAPT (N-[(3,5-difluorophenyl)acetyl]-L-
alanyl-2-phenylglycine-1,1-dimethylethyl ester) led to
the accumulation of the TREM2 CTF, thereby signifi-
cantly increasing the ratio of CTF/full-length TREM2
(Fig. 1a).
Our previous data revealed that inhibition of γ-
secretase decreased the phosphorylation of the TREM2
co-receptor DAP12 and stabilized PIP2 levels at the
plasma membrane, suggesting impaired activation of
PLCγ [18]. Because PLCγ plays a major role in the regu-
lation of intracellular Ca2+ signaling, we next analyzed
the effect of γ-secretase inhibition on TREM2-
dependent changes in intracellular Ca2+ concentrations
([Ca2+]i). TREM2 was specifically stimulated with anti-
myc antibody, and changes in [Ca2+]i were monitored by
Fluo-4 AM (Life Technologies, USA) imaging. Cell incu-
bation with anti-myc caused a significant increase in
cytosolic [Ca2+]i (Fig. 1b). An isotype control antibody
did not evoke a signal (not shown), indicating that spe-
cific activation of TREM2 results in elevation of [Ca2+]i.
Interestingly, pharmacological inhibition of γ-secretase
with DAPT efficiently blocked the elevation of [Ca2+]i
upon activation of TREM2 (Fig. 1b).
It has been shown previously that activation of
TREM2 induces changes in cellular morphology [19].
Thus, we next tested morphological changes of cells
upon activation of TREM2 in the presence or absence of
γ-secretase inhibition. Cells expressing myc-tagged
TREM2 were monitored by live cell microscopy in the
presence of anti-myc or isotype control antibodies. Cell
incubation with anti-myc antibody, but not with the iso-
type control (data not shown), resulted in a time-
dependent decrease in cell surface area (Fig. 1c). Not-
ably, inhibition of γ-secretase completely blocked the
TREM2-dependent changes in cellular morphology
(Fig. 1c).
To test whether the addition of anti-myc antibody to
living cells affects the processing of TREM2 under the
experimental conditions, we analyzed levels of full-
length TREM2 and its CTFs by Western immunoblot-
ting. However, treatment with anti-myc antibody did not
affect the generation of TREM2-CTF (Fig. 1d).
Decreased TREM2-dependent phagocytosis upon inhibition
of γ-secretase activity
TREM2 is predominantly expressed in monocyte-derived
cells, including macrophages and microglia, and modu-
lates phagocytosis [2]. However, functional investigation of
endogenous TREM2 is hampered by the lack of a selective
ligand for TREM2. We adapted our heterologous expres-
sion system to the mouse microglial cell line BV-2. BV-2
cells endogenously express functional PS1 and PS2 pro-
teins as indicated by the detection of characteristic N-
terminal and C-terminal fragments derived from endo-
proteolytic processing of the full-length proteins during
incorporation and maturation of the γ-secretase complex
(Fig. 2a). In contrast, endogenous TREM2 could not be
detected by Western immunoblotting (not shown).
BV-2 cells were transfected with the myc-tagged
variant of TREM2 as described above, and phagocyt-
osis of latex beads was assessed by live cell micros-
copy upon incubation for 2 h in the absence or
presence of antibodies against the myc epitope to se-
lectively activate TREM2 (Fig. 2b, c; Additional file 1:
Movie 1). The fraction of cells with less than three
beads was significantly lower upon activation with
anti-myc antibody (40.82 ± 7.63 %) in comparison to
cells treated with an isotype control antibody (65.83 ±
5.78 %). This effect was not observed after pretreat-
ment of cells with the γ-secretase inhibitor DAPT
(58.80 ± 4.62 %; Fig. 2c). The fraction of cells with
three to five internalized beads slightly increased from
32.01 ± 5.21 % in cultures incubated with an isotype
control antibody to 46.12 ± 3.96 % in cultures incu-
bated with the anti-myc antibody (Fig. 2c). However,
this effect was not statistically significant. The frac-
tion of cells which have internalized six or more
beads, thus reflecting high phagocytic activity, signifi-
cantly increased from 2.55 ± 1.41 % (isotype control)
to 13.06 ± 5.50 % upon specific activation of TREM2
(with anti-myc antibody), representing an aproximat-
ley fivefold stimulation (Fig. 2c). These data indicate
that selective activation of TREM2 stimulates the
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Fig. 1 Inhibition of γ-secretase impairs TREM2-dependent Ca2+ signaling. a COS7 cells were transfected with mouse myc-TREM2-FL-GFP or control
vector encoding GFP only. Constructs encoding TREM2 and DAP12 have been described earlier [18]. TREM2 was always co-transfected with DAP12 to
allow efficient subcellular transport [15, 22]. Expression of TREM2-FL and TREM2-CTF was analyzed by Western immunoblotting using either anti-myc
or anti-GFP antibodies. The γ-secretase inhibitor DAPT (1 μM, 18 h pretreatment) significantly increased the ratio of TREM2-CTF to TREM2-FL (***p <
0.001; n = 3). b Ratiometric determination of intracellular Ca2+ levels upon anti-myc antibody induced TREM2 activation in the absence or presence of
DAPT (1 μM, 18 h pretreatment). COS7 cell treatment with DAPT attenuates the TREM2-evoked increase in intracellular [Ca2+] (****p < 0.0001;
n = 4–6). c Morphological change upon activation of TREM2 in the absence or presence of DAPT. COS7 cells co-expressing mouse myc-TREM2-GFP
and DAP12 were seeded onto coverslips and monitored by light microscopy for 10 min to determine spontaneous changes of the cell area. After
10 min, monoclonal anti-myc antibodies were added to the medium and cells were imaged for additional 2 h. Changes in cell surface area were
determined by subtraction of the area after 2 h of stimulation from that before stimulation. Activation of TREM2 with anti-myc antibody
induced a significant decrease in cell size (*p < 0.05). The inhibition of γ-secretase with DAPT prevented the TREM2-induced shrinkage of
cells (*p < 0.05; n = 3). d COS7 cells were transfected with mouse myc-TREM2-FL-GFP and treated with anti-myc antibody for 2 h after
overnight incubation with or without DAPT. TREM2 FL and CTFs were detected by western immunobloting
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Fig. 2 Inhibition of γ-secretase activity decreases TREM2-dependent phagocytosis in microglial BV-2 cells. a Analysis of endogenous γ-secretase
components PS1 and PS2 in microglial BV-2 cells by Western immunoblotting. Characteristic N-terminal fragment (NTF) and C-terminal fragment
(CTF) of PS1 and PS2 were detected, indicating endogenous expression of both PS proteins. P-PS1 CTF denotes the migration of a phosphorylated
variant of the PS1 CTF. b, c BV-2 cells were seeded on μ-IBIDI dishes (IBIDI, Germany) and transfected with myc-TREM2-GFP. Cells were cultured in
the absence or presence of 1 μM of DAPT for 24 h. Four microliters of latex beads (Sigma-Aldrich, USA) was added, and TREM2 was stimulated
for 2 h by addition of anti-myc antibody. Uptake of latex beads was analyzed by light microscopy (*p < 0.05; **p < 0.01; n = 97–105 cells per
condition). Arrow heads indicate internalized leads. d BV-2 cells with endogenous expression of PS1 and PS2 (see a) were preincubated in the
absence or presence of DAPT (d) for 24 h. Cells were stimulated with anti-myc antibodies, and changes in [Ca2+]i were monitored by fluorescence
microscopy. Treatment with DAPT abrogated the cellular response in [Ca2+]i. e Cells stably overexpressing PS1 wild type (PS1 WT) or a dominant-
negative variant of PS1 (PS1 DN) were stimulated with anti-myc. Only cells expressing PS1 WT, but not PS1 DN, responded to TREM2 activation
with an increase in [Ca2+]i. As observed in cells with endogenous PS expression, pretreatment of PS1 WT-overexpressing cells with DAPT also
inhibited the increase in [Ca2+]i (****p < 0.0001; n = 3 to 11 cells per condition)
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phagocytic activity of BV-2 cells. Interestingly, inhibition
of γ-secretase activity by preincubation of cells with DAPT
significantly decreased the TREM2-mediated stimulation
of phagocytosis to basal levels of cells incubated with iso-
type control antibodies (Fig. 2c).
We next assessed effects of γ-secretase inhibition on
Ca2+ signaling in BV-2 cells. As described above for
COS7 cells, stimulation of TREM2 overexpressing BV-2
cells resulted in increased [Ca2+]i. Inhibition of γ-
secretase by DAPT strongly inhibited the elevation of
[Ca2+]i (Fig. 2d). We also used a genetic approach to in-
hibit γ-secretase activity (Fig. 2e). BV-2 cells were stably
transfected with a dominant-negative variant of PS1
(PS1 DN), which has a mutation in its active site and
thus is inactive [18]. Since this variant associated with
other components of the γ-secretase complex, it sup-
presses endogenous γ-secretase activity [18]. Cells stably
overexpressing the wild-type PS1 (PS1 WT) were used
as control. Activation of myc-tagged TREM2 in PS1
WT-overexpressing cells increased [Ca2+]i. In contrast,
cells expressing the PS1 DN did not respond to stimula-
tion of TREM2. The response of PS1 WT-expressing
cells was also decreased upon pharmacological γ-
secretase inhibition with DAPT (Fig. 2e).
The present data revealed that γ-secretase activity is
important to control the signaling function of TREM2.
The physiological functions of TREM2 are not fully
understood. On the one hand, macrophages of TREM2
knockout (KO) mice show increased production of
inflammatory cytokines upon Toll-like receptor activa-
tion [20] and decreased phagocytic activity [15]. On the
other hand, activation of TREM2 in microglia increased
the expression of chemokine receptors and cell migra-
tion [21, 22]. Thus, TREM2 could exert complex func-
tions in cellular activation. Interestingly, homozygous
mutations in TREM2 have been shown to cause Nasu-
Hakola disease and FTD, while the heterozygous R47H
variant is associated with an increased risk for develop-
ment of AD [11, 16, 23]. Several of these disease-
associated mutations impair transport in the secretory
pathway and result in lower glycosylation and expression
at the cell surface [16, 17]. HEK293 or BV-2 cells over-
expressing mutant TREM2 showed decreased phagocytic
activity as compared to cells expressing WT TREM2,
suggesting that the mutations of TREM2 cause a loss of
function [16]. Recent data also showed that the deletion
of TREM2 led to decreased clustering of microglia
around amyloid plaques in a mouse model of AD and
also decreased the phagocytic activity [14]. Another
study also showed decreased number of myeloid cells in
brains of TREM2 KO mice crossed with APP transgenic
mice [15]. However, cells associated with plaques in this
model revealed characteristics of peripheral macro-
phages that might invade the brain [15].
Our present data revealed that inhibition of γ-
secretase activity also decreased TREM2-dependent sig-
naling and phagocytosis. A role of γ-secretase in micro-
glial phagocytosis and migration has been shown
Fig. 3 Hypothetical model of TREM2-dependent signaling in cells with and without functional γ-secretase. Degradation of TREM2 CTFs by
γ-secretase allows an efficient association of full-length TREM2 with its co-receptor DAP12. Upon ligand binding to TREM2, DAP12 undergoes
phosphorylation within its intracellular ITAM domain, resulting in the recruitment of the spleen tyrosine kinase (Syk) and activation of phospholipase C
(PLC). PLC-mediated cleavage of phosphatidylinositol-4,5-bisphosphate in cellular membranes leads to generation of inositol-1,4,5-trisphosphate (IP3)
and mobilization in Ca2+ from the endoplasmic reticulum, thereby regulating phagocytosis and dynamics of the cytoskeleton. Upon inhibition of γ-
secretase, DAP12 might predominantly associate with accumulated TREM2 CTFs, thereby decreasing the availability to bind to full-length TREM2, which
would result in impaired signal transduction
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previously. Isolated microglia from PS2 KO mice showed
decreased phagocytosis and migration [24, 25], but the
molecular mechanisms were unclear. The present data
could suggest that impaired processing of the TREM2
CTF by γ-secretase might contribute to these previously
observed effects. The signaling of TREM2 requires inter-
action with its co-receptor DAP12. We previously
showed that the accumulation of TREM2 CTFs alters
the distribution and association of DAP12 with full-
length TREM2 at the plasma membrane [18]. Together
with the present data, these findings suggest that accu-
mulated TREM2 CTFs might trap DAP12 and thereby
interfere with TREM2 signaling (Fig. 3).
A recent study showed that DAP12 overexpression
could stabilize TREM2 CTFs [25]. In turn, the overex-
pression of TREM2 CTF impaired the secretion of
inflammatory cytokines upon cell exposure to lipopoly-
saccharide, also supporting the notion that efficient
clearance of CTFs is critical for proper signaling func-
tion of TREM2 [25].
The present data demonstrate an important function of
γ-secretase activity in the signal transduction of TREM2.
The inhibition of γ-secretase impaired Ca2+ signaling and
phagocytic activity of TREM2-expressing cells. Thus,
these findings support a functional involvement of two
critical genetic factors of AD in the same signaling path-
way. The functional connection of γ-secretase and
TREM2 should be considered in the pharmacological tar-
geting of γ-secretase in the treatment of AD.
Additional file
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